Scott Anjewierden

Title: Scott Anjewierden: Innovator in Cardiac Assessment Technology

Introduction

Scott Anjewierden is a notable inventor based in Rochester, MN (US). He has made significant contributions to the field of cardiac health through his innovative patent. His work focuses on improving the assessment of myocardial viability, which is crucial for treating conditions such as atrial fibrillation.

Latest Patents

Scott Anjewierden holds a patent titled "Assessment of atrial myocardial viability using spectral analysis of ultrasound." This patent describes a method where spectral parameters of ultrasound backscatter from myocardial tissue can be utilized to identify fibrosis and accurately assess myocardial viability during ablation procedures. The process involves ultrasonically insonifying a portion of myocardial tissue, measuring the backscatter signal of ultrasonic waves, determining a spectral parameter of the backscatter signal, and correlating this parameter with the electrical conductivity of the myocardial tissue. This correlation can then inform or adjust treatment decisions for patients.

Career Highlights

Scott Anjewierden is associated with the Cleveland Clinic Foundation, a prestigious institution known for its commitment to medical innovation and research. His work there has allowed him to focus on developing advanced techniques for cardiac assessment, contributing to better patient outcomes.

Collaborations

Some of his notable coworkers include Russell Fedewa and Oussama Wazni. Their collaboration in the field of cardiac health has further enhanced the research and development of innovative solutions.

Conclusion

Scott Anjewierden's contributions to cardiac assessment technology through his patent demonstrate his commitment to improving patient care. His innovative approach to utilizing ultrasound technology in assessing myocardial viability is a significant advancement in the medical field.